Specifically, they observed increased MR expression in experimental and human Pulmonary Arterial Hypertension (PAH), while in idiopathic PAH patients, finerenone treatment or siRNA-mediated MR silencing reduced the proliferation of pulmonary artery smooth muscle cells (PA-SMCs) (14). The gene discussed is NR3C2; the disease is pulmonary arterial hypertension.